HempNewsBreaks – International Endeavors Corp. (IDVV) Enters MOU with Kubby Cryogenics, Inc. to Expand Medical Cannabis Line

International Endeavors (OTC: IDVV) this morning said that it has signed a memorandum of understanding (MOU) with Kubby Cryogenics, Inc. Per the agreement, Kubby Cryogenics will seek to patent medical grade cannabis strains that are genetically profiled to treat specific diseases. The agreement also states that Steve Kubby will immediately become CEO of International Endeavors. Kubby Cryogenics has assembled a team of top scientists and geneticists to continue developing the company’s proprietary cryogenics products. “We will create a dispensary system for legal medical cannabis states standardizing the patient centered, consultation approach while presenting an enticing line of Adult Use products featuring a patent pending menu of powerful strains and pure, all natural, solvent-less concentrate products,” International Endeavors incoming CEO Steve Kubby stated in the news release.

To view the full press release, visit: http://cnw.fm/Mgj72

About International Endeavors Corporation

International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com

More from CannabisNewsBreaks

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net

Chris@HW

Share
Published by
Chris@HW

Recent Posts

HempNewsBreaks – Turning Point Brands Inc. (NYSE: TPB) Closes $300M Senior Secured Notes Offering 

Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…

2 months ago

HempNewsBreaks – WEED Inc. (BUDZ) Announces 2024 Highlights, Plans to Expand into Consumer Packaged Goods

WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…

4 months ago

HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes $3.6M Registered Direct

Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…

4 months ago

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) to Host Spaces Event, Share Comprehensive Update on Destino Ranch

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced its plans to host a Spaces call…

5 months ago

HempNewsBreaks – CBD Life Sciences Inc. (CBDL) Poised to Become Game Changer in the Hemp Industry

CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70…

6 months ago

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that…

7 months ago